Novo Nordisk Partners With Metaphore Biotechnologies on New Obesity Drugs
By Helena Smolak
Ozempic maker Novo Nordisk signed a research collaboration with U.S. biotech company Metaphore Biotechnologies to develop up to two advanced obesity treatments, which could cost the company up to $600 million.
Metaphore Biotechnologies said on Thursday that the Danish drug company, which makes weight-loss drugs Ozempic and Wegovy, will use Metaphore's tech platform, which combines machine learning with molecular mimicry, to develop the treatments.
This is the third research and development deal with Metaphore Biotechnologies' parent company Flagship Pioneering.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
May 09, 2024 10:30 ET (14:30 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks